SEC Comment Letter 0000000000-23-009855 to MoonLake Immunotherapeutics (MLTX) (CIK 0001821586) (MLTX)
MoonLake Immunotherapeutics (MLTX) (CIK 0001821586)
Date: Sept. 6, 2023 · CIK: 0001821586 · Accession: 0000000000-23-009855
AI Filing Summary & Sentiment
File numbers found in text: 333-274286
Letter
United States securities and exchange commission logo September 6, 2023 Matthias Bodenstedt Chief Financial Officer MoonLake Immunotherapeutics Dorfstrasse 29 6300 Zug Switzerland 41 415108022 Re:MoonLake Immunotherapeutics Registration Statement on Form S-3 Filed August 31, 2023 File No. 333-274286 Dear Matthias Bodenstedt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Branden Berns
Show Raw Text
United States securities and exchange commission logo
September 6, 2023
Matthias Bodenstedt
Chief Financial Officer
MoonLake Immunotherapeutics
Dorfstrasse 29
6300 Zug
Switzerland
41 415108022
Re:MoonLake Immunotherapeutics
Registration Statement on Form S-3
Filed August 31, 2023
File No. 333-274286
Dear Matthias Bodenstedt:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Branden Berns